Advanced gastric cancer: What we know and what we still have to learn

Figure 1 Overall 1-year (A), 2-year (B), 3-year (C) or 5-year (D) survival in patients undergone to CC0-CC1 procedure[62].

Figure 2 One-year (A) or 3-year (B) survival compared between CC0 and CC1 cytoreduction[62].

Figure 3 Overall 1-year (A), 2-year (B) or 3-year (C) mortality in intraperitoneal chemotherapy[102].

Figure 4 Two-year (A) or three-year (B) mortality in patients with locoregional nodal metastasis[102].

Figure 5 One-year (A) or 2-year (B) mortality in patients with serosal infilatration[102].

Figure 6 Overall (A) or peritoneal (B) recurrence in patients treated with intraperitoneal chemotherapy[102].